JP2014012738A - 免疫優性な共有黒色腫抗原を発現する黒色腫細胞株およびその使用方法 - Google Patents

免疫優性な共有黒色腫抗原を発現する黒色腫細胞株およびその使用方法 Download PDF

Info

Publication number
JP2014012738A
JP2014012738A JP2013218131A JP2013218131A JP2014012738A JP 2014012738 A JP2014012738 A JP 2014012738A JP 2013218131 A JP2013218131 A JP 2013218131A JP 2013218131 A JP2013218131 A JP 2013218131A JP 2014012738 A JP2014012738 A JP 2014012738A
Authority
JP
Japan
Prior art keywords
melanoma
cell line
same
line expressing
melanoma cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2013218131A
Other languages
English (en)
Inventor
Drew M Pardoll
エム． パードル ドゥリュー
Elizabeth M Jaffee
エム． ジャフィー エリザベス
Adam Adler
アドゥラー アダム
Suzanne L Topalian
エル． トパリアン スザンヌ
Steven A Rosenberg
エイ． ローゼンバーグ スティーヴン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
US Government
School of Medicine of Johns Hopkins University
Original Assignee
Johns Hopkins University
US Government
School of Medicine of Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University, US Government, School of Medicine of Johns Hopkins University filed Critical Johns Hopkins University
Publication of JP2014012738A publication Critical patent/JP2014012738A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

【課題】従来技術では達成できなかった効果を有する、免疫優性な共有黒色腫抗原を発現する黒色腫細胞株およびその使用方法の提供。
【解決手段】(a) １または２以上の免疫優性な共有黒色腫抗原を発現する黒色腫細胞株を取得し、 (b) 未改変黒色腫細胞株に比べてサイトカインの産生レベルが増加し得るよう
に該黒色腫細胞株を改変し、(c) 黒色腫を有するかあるいは黒色腫が発生する危険のある哺乳動物宿主に該黒色腫細胞株を投与することを含む、黒色腫の治療または予防方法。
【選択図】なし

Description
本発明によって以下が提供される：

Claims (1)

  1. 本願明細書に記載されるような、免疫優性な共有黒色腫抗原を発現する黒色腫細胞株およびその使用方法。
JP2013218131A 1996-08-16 2013-10-21 免疫優性な共有黒色腫抗原を発現する黒色腫細胞株およびその使用方法 Withdrawn JP2014012738A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2409896P 1996-08-16 1996-08-16
US60/024,098 1996-08-16

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2011168822A Division JP2012001548A (ja) 1996-08-16 2011-08-01 免疫優性な共有黒色腫抗原を発現する黒色腫細胞株およびその使用方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016043177A Division JP2016106137A (ja) 1996-08-16 2016-03-07 免疫優性な共有黒色腫抗原を発現する黒色腫細胞株およびその使用方法

Publications (1)

Publication Number Publication Date
JP2014012738A true JP2014012738A (ja) 2014-01-23

Family

ID=21818860

Family Applications (5)

Application Number Title Priority Date Filing Date
JP50973298A Withdrawn JP2001517206A (ja) 1996-08-16 1997-08-04 免疫優性な共有黒色腫抗原を発現する黒色腫細胞株およびその使用方法
JP2007284431A Withdrawn JP2008044969A (ja) 1996-08-16 2007-10-31 免疫優性な共有黒色腫抗原を発現する黒色腫細胞株およびその使用方法
JP2011168822A Withdrawn JP2012001548A (ja) 1996-08-16 2011-08-01 免疫優性な共有黒色腫抗原を発現する黒色腫細胞株およびその使用方法
JP2013218131A Withdrawn JP2014012738A (ja) 1996-08-16 2013-10-21 免疫優性な共有黒色腫抗原を発現する黒色腫細胞株およびその使用方法
JP2016043177A Pending JP2016106137A (ja) 1996-08-16 2016-03-07 免疫優性な共有黒色腫抗原を発現する黒色腫細胞株およびその使用方法

Family Applications Before (3)

Application Number Title Priority Date Filing Date
JP50973298A Withdrawn JP2001517206A (ja) 1996-08-16 1997-08-04 免疫優性な共有黒色腫抗原を発現する黒色腫細胞株およびその使用方法
JP2007284431A Withdrawn JP2008044969A (ja) 1996-08-16 2007-10-31 免疫優性な共有黒色腫抗原を発現する黒色腫細胞株およびその使用方法
JP2011168822A Withdrawn JP2012001548A (ja) 1996-08-16 2011-08-01 免疫優性な共有黒色腫抗原を発現する黒色腫細胞株およびその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016043177A Pending JP2016106137A (ja) 1996-08-16 2016-03-07 免疫優性な共有黒色腫抗原を発現する黒色腫細胞株およびその使用方法

Country Status (8)

Country Link
US (1) US6187306B1 (ja)
EP (1) EP0929318B1 (ja)
JP (5) JP2001517206A (ja)
AT (1) ATE283069T1 (ja)
AU (1) AU3889997A (ja)
CA (1) CA2263503C (ja)
DE (1) DE69731756T2 (ja)
WO (1) WO1998006746A2 (ja)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102666663A (zh) * 2009-10-23 2012-09-12 道康宁东丽株式会社 新的有机聚硅氧烷共聚物

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096313A (en) * 1996-02-09 2000-08-01 Ludwig Institute For Cancer Research Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
US6277368B1 (en) 1996-07-25 2001-08-21 The Regents Of The University Of California Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine
US5891432A (en) 1997-07-29 1999-04-06 The Immune Response Corporation Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same
EP1069917A4 (en) * 1998-03-20 2005-02-09 Genzyme Corp NEW COMPLEMENTARY PAIRS OF RECEPTORS / LIGANDS AND ADOPTIVE IMMUNOTHERAPY USING THE SAME
GB9810040D0 (en) 1998-05-11 1998-07-08 Univ Nottingham Blood borne tumour markers
US6316420B1 (en) * 1998-07-28 2001-11-13 Technion Research And Development Foundation Ltd. DNA cytokine vaccines and use of same for protective immunity against multiple sclerosis
GB9827228D0 (en) * 1998-12-10 1999-02-03 Univ Nottingham Cancer detection method and reagents
DE19905501B4 (de) 1999-02-10 2005-05-19 MediGene AG, Gesellschaft für molekularbiologische Kardiologie und Onkologie Verfahren zur Herstellung eines rekombinanten Adeno-assoziierten Virus, geeignete Mittel hierzu sowie Verwendung zur Herstellung eines Arzneimittels
US20030232399A1 (en) * 2000-06-14 2003-12-18 Robertson John Forsyth Russell Cancer detection methods and reagents
WO2001098464A2 (en) * 2000-06-22 2001-12-27 Aventis Pasteur Limited Continuous adherent melanocyte cell line
CN1756568A (zh) 2002-10-09 2006-04-05 衣阿华中央卫生系统 使用表达α(1,3)－半乳糖基转移酶的同种异型肿瘤细胞的抗肿瘤免疫
US20050201993A1 (en) * 2002-10-09 2005-09-15 Link Charles J.Jr. Antitumor vaccination using allogeneic tumor cells expressing alpha (1,3)-galactosyltransferase
GB2424070B (en) * 2002-11-14 2007-06-27 Univ Nottingham Methods for preparing tumour marker proteins
US20050136035A1 (en) * 2003-06-03 2005-06-23 Derek Ko Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site
WO2005017149A1 (en) * 2003-06-03 2005-02-24 Cell Genesys, Inc. Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
US20050186178A1 (en) * 2003-08-28 2005-08-25 Ennist David L. Oncolytic adenoviral vectors encoding GM-CSF
SI1889059T1 (sl) 2005-05-27 2009-12-31 Oncimmune Ltd Izboljšani imunotestni postopek
GB2426581A (en) * 2005-05-27 2006-11-29 Univ Nottingham Immunoassay methods
JP6092497B2 (ja) 2006-03-30 2017-03-08 ユニバーシティー オブ カリフォルニア 抗ｃｔｌａ−４抗体の限局性分泌のための方法および組成物
US7919079B2 (en) * 2006-03-31 2011-04-05 Biosante Pharmaceuticals, Inc. Cancer immunotherapy compositions and methods of use
US8574848B2 (en) * 2006-09-13 2013-11-05 Oncimmune Ltd. Immunoassay methods
US7998486B2 (en) 2006-10-25 2011-08-16 Newlink Genetics Corporation Enhanced immunogenicity of tumor associated antigens by addition of alphaGal epitopes
AR060424A1 (es) * 2007-04-11 2008-06-18 Consejo Nac Invest Cient Tec Lineas celulares , composiciones para el tratamiento de melanomas que las comprenden procedimientos para preparar las composiciones y metodos de tratamiento
GB0725239D0 (en) * 2007-12-24 2008-02-06 Oncimmune Ltd Calibrator for autoantibody assay
JP7409773B2 (ja) 2015-07-31 2024-01-09 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 改変された細胞および治療の方法
EP4338799A3 (en) 2016-10-18 2024-06-05 Regents of the University of Minnesota Tumor infiltrating lymphocytes and methods of therapy
WO2019006418A2 (en) 2017-06-30 2019-01-03 Intima Bioscience, Inc. ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07278193A (ja) * 1994-02-16 1995-10-24 Akzo Nobel Nv 黒色腫関連抗原ポリペプチド、そのエピトープ及び黒色腫のワクチン
WO1995029193A2 (en) * 1994-04-22 1995-11-02 The Government Of The United States Of America Represented By The Secretary, Department Of Health And Human Services Melanoma antigens

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4595653A (en) 1981-06-09 1986-06-17 Lee Biomolecular Research Laboratories, Inc. Process for assaying cellular immunity
US5045320A (en) 1989-03-23 1991-09-03 Medical Biology Institute Large multivalent immunogen
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
DE69114299T3 (de) 1990-09-14 2005-09-15 The Johns Hopkins University Verfahren und zusammensetzungen für gentherapie und stärkung des immunsystems.
US5342774A (en) 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
US5637483A (en) * 1991-10-04 1997-06-10 Whitehead Institute For Biomedical Research Irradiated tumor cell vaccine engineered to express GM-CSF
EP1216710B1 (en) * 1991-10-04 2006-04-05 Whitehead Institute For Biomedical Research Regulation of systemic immune responses utilizing cytokines and antigens
US5759535A (en) * 1994-05-13 1998-06-02 Research Corporation Technologies, Inc. Immunotherapeutic strategies for the treatment of cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07278193A (ja) * 1994-02-16 1995-10-24 Akzo Nobel Nv 黒色腫関連抗原ポリペプチド、そのエピトープ及び黒色腫のワクチン
WO1995029193A2 (en) * 1994-04-22 1995-11-02 The Government Of The United States Of America Represented By The Secretary, Department Of Health And Human Services Melanoma antigens

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
JPN4007020209; Ｃａｎｃｅｒ　Ｒｅｓｅａｒｃｈ Ｖｏｌ．５６，Ｎｏ．９, 199605, ｐ２１９１-２１９８ *
JPN4007020210; Ｐｒｏｃ．Ｎａｔｌ．Ａｃａｄ．Ｓｃｉ．Ｕ．Ｓ．Ａ． Ｖｏｌ．９０，Ｎｏ．８, 1993, ｐ３５３９-３５４３ *
JPN4007020211; Ｐｒｏｃ．Ｎａｔｌ．Ａｃａｄ．Ｓｃｉ．Ｕ．Ｓ．Ａ． Ｖｏｌ．９１，Ｎｏ．２０, 1994, ｐ９４６１-９４６５ *
JPN4007020212; Ｊｏｕｒｎａｌ　ｏｆ　Ｉｎｖｅｓｔｉｇａｔｉｖｅ　Ｄｅｒｍａｔｏｌｏｇｙ Ｖｏｌ．８５，Ｎｏ．５, 1985, ｐ４２６-４３０ *
JPN4007020213; Ｓｃｉｅｎｃｅ Ｖｏｌ．２６４, 1994, ｐ９６１-９６５ *
JPN4007020214; Ｊｏｕｒｎａｌ　ｏｆ　Ｅｘｐｅｒｉｍｅｎｔａｌ　Ｍｅｄｉｃｉｎｅ Ｖｏｌ．１７６，Ｎｏ．５, 1992, ｐ１４５３-１４５７ *
JPN4007020215; Ｊｏｕｒｎａｌ　ｏｆ　Ｅｘｐｅｒｉｍｅｎｔａｌ　Ｍｅｄｉｃｉｎｅ Ｖｏｌ．１７９，Ｎｏ．３, 1994, ｐ９２１-９３０ *
JPN4007020216; Ｐｒｏｃ．Ｎａｔｌ．Ａｃａｄ．Ｓｃｉ．Ｕ．Ｓ．Ａ． Ｖｏｌ．９１，Ｎｏ．９, 1994, ｐ３５１５-３５１９ *
JPN4007020217; Ｊｏｕｒｎａｌ　ｏｆ　Ｅｘｐｅｒｉｍｅｎｔａｌ　Ｍｅｄｉｃｉｎｅ Ｖｏｌ．１７８，Ｎｏ．２, 1993, ｐ４８９-４９５ *
JPN4007020218; Ｊｏｕｒｎａｌ　ｏｆ　Ｅｘｐｅｒｉｍｅｎｔａｌ　Ｍｅｄｉｃｉｎｅ Ｖｏｌ．１７９，Ｎｏ．３, 1994, ｐ１００５-１００９ *
JPN4007020219; Ｐｒｏｃ．Ｎａｔｌ．Ａｃａｄ．Ｓｃｉ．Ｕ．Ｓ．Ａ． Ｖｏｌ．９１，Ｎｏ．１４, 1994, ｐ６４５８-６４６２ *
JPN6011057760; Ｊｏｕｒｎａｌ　ｏｆ　Ｉｍｍｕｎｏｔｈｅｒａｐｙ　ｗｉｔｈ　Ｅｍｐｈａｓｉｓ　ｏｎ　Ｔｕｍｏｒ　Ｉｍ Ｖｏｌ．１９，Ｎｏ．３, 199505, ｐ１７６-１８３ *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102666663A (zh) * 2009-10-23 2012-09-12 道康宁东丽株式会社 新的有机聚硅氧烷共聚物

Also Published As

Publication number Publication date
WO1998006746A2 (en) 1998-02-19
WO1998006746A3 (en) 1998-05-07
CA2263503C (en) 2012-04-10
ATE283069T1 (de) 2004-12-15
US6187306B1 (en) 2001-02-13
EP0929318A2 (en) 1999-07-21
AU3889997A (en) 1998-03-06
DE69731756T2 (de) 2005-12-15
JP2016106137A (ja) 2016-06-16
DE69731756D1 (de) 2004-12-30
CA2263503A1 (en) 1998-02-19
JP2012001548A (ja) 2012-01-05
EP0929318B1 (en) 2004-11-24
JP2008044969A (ja) 2008-02-28
JP2001517206A (ja) 2001-10-02

Similar Documents

Publication Publication Date Title
JP2014012738A (ja) 免疫優性な共有黒色腫抗原を発現する黒色腫細胞株およびその使用方法
EP1018683A3 (en) Executable for requesting a linguistic service
TR199902803T2 (xx) VCAM-1' in te�hisinin daralt�lmas� i�in bile�ikler ve metodlar.
JP2005270111A (ja) パピローマウイルス様粒子、融合タンパク質並びにそれらの製造方法
ATE197592T1 (de) Monoklonaler antikörper gegen cd44v6
JP2008086326A (ja) ゲノム性要素を使用する遺伝子の操作および発現
SE8307060L (sv) Diagnostikum och kontrastmedel
DK0862633T3 (da) VP-antigen af JC-virus
ES2143507T3 (es) Vacunas contra la enfermedad de aujeszky y de otras enfermedades animales que contienen mutantes del virus de la pseudorrabia.
ATE212058T1 (de) Herstellung von einer immunantwort gegen prostat- spezifisches antigen (psa)
TR199701544T1 (xx) Yeni dolastatin t�revleri,bunlar�n haz�rlanmas� ve kullan�lmas�.
IL139601A0 (en) Compositions and methods of modulating an immune response to an antigen
HU9601981D0 (en) T cell stimulating protein of pestivirus
IT8422362A0 (it) Metodo per preparare una sospensione acquosa di particelledi combustibile carbonioso solido e sospensione acquosa cosi'preparata.
DE69615537T2 (de) Helicobacter pylori antigen
SU627922A1 (ru) Цанговый патрон
ATE148694T1 (de) Verfahren zur herstellung von 3(5)- methylpyrazolen
SU700723A2 (ru) Косозуба зубчата передача
SU635271A1 (ru) Детандер
SU566892A1 (ru) Катодное устройство
McCoy Replica techniques for transmission electron microscopy
KR840001833A (ko) 개 파보불화화 백신의 제조방법

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20131021

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141125

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150209

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20151106

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20160809